Want to see SE:ISOFOL full AI Analyst Report?
Top Page
Isofol Medical AB
(ISOFOL)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr0.82
▲(14.17% Upside)
Action:Reiterated
Date:07/28/26
The score is constrained primarily by very weak fundamentals (no revenue, continued losses, and negative operating cash flow alongside declining equity). Technicals are a partial offset with the stock trading above major moving averages, but valuation remains challenged given negative earnings and no dividend data.
Positive Factors
Proprietary lead asset
Having a proprietary, clinical‑stage asset (arfolitixorin) focused on combinations with broadly used 5‑FU chemo is a durable strategic strength. It supports potential licensing, partnerships, or future commercial revenue if trials and approvals progress, underpinning long‑term value creation.
Negative Factors
No revenue base
Zero revenue is a structural weakness: without a commercial product the firm must rely on financing or partnerships to fund development. This absence of recurring sales creates long lead times to profitability and sustained reliance on external capital, raising execution risk long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary lead asset
Having a proprietary, clinical‑stage asset (arfolitixorin) focused on combinations with broadly used 5‑FU chemo is a durable strategic strength. It supports potential licensing, partnerships, or future commercial revenue if trials and approvals progress, underpinning long‑term value creation.
Read all positive factors
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr262.16M
Dividend YieldN/A
Average Volume (3M)501.89K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue GrowthN/A
EPS Growth9.40%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Isofol Medical AB Business Overview & Revenue Model
Company Description
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is ...
How the Company Makes Money
null...
Isofol Medical AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 721.00K | 12.80M | 22.41M |
| Gross Profit | -11.49M | 0.00 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -56.77M | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -55.57M | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | ||||||
| Total Assets | 113.91M | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 110.74M | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 3.95M | 1.65M |
| Total Liabilities | 21.08M | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 92.83M | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | ||||||
| Free Cash Flow | -3.65M | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -55.58M | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 101.00K | 0.00 | 0.00 |
| Financing Cash Flow | 84.07M | 84.07M | 0.00 | 0.00 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Neutral
0.72
Price Trends
0.77
Positive
0.74
Positive
0.71
Positive
Market Momentum
0.02
Positive
51.05
Neutral
29.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Neutral. The current price of 0.72 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.77, and above the 200-day MA of 0.71, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.05 is Neutral, neither overbought nor oversold. The STOCH value of 29.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ISOFOL.
Isofol Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr493.12M | 2.72 | 77.69% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr425.64M | -3.53 | -17.87% | ― | ― | 15.97% | |
47 Neutral | kr262.16M | -3.27 | -59.93% | ― | ― | 9.40% | |
45 Neutral | kr670.44M | -1.86 | ― | ― | 109.22% | 27.30% | |
44 Neutral | kr1.58B | -4.52 | -53.88% | ― | 258.30% | 28.33% | |
42 Neutral | kr176.52M | -8.97 | -56.67% | ― | ― | 43.32% |
* Healthcare Sector Average
SE:ISOFOL
Isofol Medical AB
0.80
-0.06
-6.87%
SE:BINV
BioInvent International AB
23.00
-13.85
-37.58%
SE:ONCO
Oncopeptides AB
1.74
-1.84
-51.39%
SE:ELIC
Elicera Therapeutics AB
2.60
-3.22
-55.30%
SE:IMMU
Immunicum AB
6.70
-0.70
-9.46%
SE:CANTA
Cantargia AB
1.85
-0.82
-30.71%
Isofol Medical AB Corporate Events
Isofol advances arfolitixorin trial with final dose cohort in colorectal cancer study
Jul 8, 2026
Isofol Medical AB has advanced its phase Ib/II clinical trial of arfolitixorin, announcing completion of the third dose level in metastatic colorectal cancer patients without dose-limiting toxicities. Following a favorable safety review, the compa...
Isofol Medical AGM Backs New Incentive Schemes and Withholds 2025 Dividend
May 19, 2026
Isofol Medical AB’s annual general meeting in Gothenburg approved the 2025 financial statements, granted discharge from liability to the board and CEO, and decided to retain earnings without distributing a dividend, underscoring a conservati...
Isofol strengthens finances and advances arfolitixorin trial in first quarter
May 19, 2026
Isofol Medical reported a first-quarter loss of SEK 15.1 million on zero revenue, while boosting cash holdings to SEK 110.7 million, supported by strong uptake of its TO1 warrants that raised about SEK 18.9 million before costs. Management highlig...
Isofol Expands Share Capital After Warrant Exercise
Apr 30, 2026
Isofol Medical AB has increased its total number of shares and votes to 320,491,623 following the recent exercise of series TO1 warrants, including a top guarantee commitment. The issuance, registered with the Swedish Companies Registration Office...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.